Therefore, we envision that the efficacious dose levels of PXL065 could potentially be achieved in patients with ALD without the known liabilities of weight gain, edema, and bone loss that are mediated by stronger PPARγ agonism (as illustrated in Figure 8). Here, PPARG is linked to X-linked adrenoleukodystrophy.